Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosis

      Abbott Logo

      News provided by

      Abbott

      Nov 19, 2026, 09:00 ET

      Share this article

      Share this article


      • Abbott's Encantor system includes software-guided deployment technology designed to help optimize valve expansion to the patient's unique anatomy, supporting precise implantation and consistent valve performance
      • Encantor early feasibility study data will be presented at PCR London Valves 2026

      ABBOTT PARK, Ill., Nov. 19, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced today it has initiated the VOYAGER CE clinical trial evaluating the safety and efficacy of its investigational Encantor™ transcatheter aortic valve implantation (TAVI) software-guided balloon-expandable system for treating symptomatic severe aortic stenosis. The first enrollment in the VOYAGER CE study occurred at Macquarie University in Sydney, Australia, led by Stephen Worthley, M.B.B.S, Ph.D.

      The prospective, single-arm, pre-market study will enroll up to 300 patients in Europe and Australia with symptomatic severe aortic stenosis caused by severe calcium buildup in the aortic valve. The study will be the basis to seek approval for use in Europe and Australia.

      "TAVI has transformed the treatment of severe aortic stenosis, but physicians continue to seek technologies that make procedures more predictable and allow treatment to be tailored to individual patients," said Didier Tchétché, M.D., director of the structural heart disease department, Clinique Pasteur, Toulouse, France, and co-principal investigator of VOYAGER CE. "Encantor's balloon-expandable design and software-guided approach are intended to give physicians greater control and procedural confidence."

      Encantor designed to treat narrowing of aortic valve

      Aortic stenosis occurs when calcium builds up in the aortic valve – which controls the flow of oxygen-rich blood to the body – and causes it to narrow. Eventually, the heart must work harder to pump blood through the narrowed valve. Left untreated, it can lead to heart failure and death.

      The investigational Encantor system works by crimping the new heart valve on a deflated surgical balloon. The balloon with the mounted valve is then inserted into the body and guided through a catheter in an artery in the groin to the heart. Once properly positioned inside the diseased aortic valve, software-guided deployment helps customize expansion of the valve to the patient's unique anatomy for a more precise fit. Once the new valve is in place, it takes over the function of the patient's damaged native valve. The balloon is then deflated and removed from the body.

      Continued research and expansion of TAVI solutions is key as the needs of physicians and patients evolve. Leveraging insights from physicians, the latest technology advancements and key learnings from the company's Navitor™ TAVI product portfolio, Abbott developed the differentiated Encantor TAVI platform to enhance procedural ease of use and controlled, precise deployment, while offering optimal blood flow (hemodynamics) through the valve.

      Early feasibility study characterizes Encantor safety and functional outcomes

      Six-month data on safety, hemodynamic and functional outcomes from the Encantor early feasibility study and an overview of the Encantor TAVI system will be presented during an innovation session on Nov. 22 at PCR London Valves 2026 (Nov. 22-24, 2026).

      Findings from the early feasibility study supported initiation of the VOYAGER CE study.

      "Our ambition is to give physicians the right technology for each patient," said Sandra Lesenfants, senior vice president of Abbott's structural heart business. "Our investigational Encantor system complements our Navitor self-expanding platform with a balloon-expandable option designed around physician insights, precise deployment and procedural ease of use. Advancing VOYAGER CE brings us another step closer to offering physicians a broader portfolio of structural heart solutions."

      Upon successful completion of clinical trials and receipt of applicable regulatory approvals, the Encantor system will further expand Abbott's comprehensive structural heart portfolio, offering physicians an additional management option to address the needs of patients.

      The Encantor balloon-expandable TAVI is investigational only and not for use anywhere in the world, including the U.S., Australia, Canada or Europe. Abbott plans to initiate a pivotal trial in the U.S. in the coming months.

      Frequently Asked Questions:

      What is aortic stenosis?
      Aortic stenosis is a heart condition in which the aortic valve becomes narrowed and stiff, blocking normal blood flow from the left ventricle into the aorta and the rest of the body. If left untreated, it can cause symptoms, such as chest pain, shortness of breath and fainting, and even weaken the heart and become life-threatening.

      How does the investigational Encantor system work?
      The investigational Encantor system is a software-guided balloon-expandable transcatheter aortic valve implantation (TAVI) device that works by crimping the new heart valve on a deflated balloon. The balloon with the mounted valve is then inserted into the body through an artery in the groin and routed up to the heart. Once properly positioned inside the narrowed heart valve, software-guided deployment helps customize expansion of the valve to the patient's unique anatomy for a more precise fit. Once the new valve is in place, it takes over the function of the patient's narrow native heart valve. The balloon is then deflated and removed from the body.

      What is the VOYAGER CE clinical trial?
      The VOYAGER CE trial is a prospective, single-arm, pre-market clinical study that will enroll people who have symptomatic heart disease due to aortic stenosis caused by severe calcium buildup in the valve. The study, which will enroll up to 300 patients in Europe and Australia, will be the basis for CE Mark approval in the Europe. The Encantor balloon-expandable transcatheter aortic valve implantation (TAVI) is investigational only and not for use anywhere in the world, including the U.S., Australia, Canada or Europe.

      What is the difference between Encantor and Abbott's current TAVI solution, Navitor?
      The key difference is how the valves expand: the investigational Encantor system uses a balloon and software guidance to expand the replacement valve inside the narrowed native valve. Abbott's current Navitor TAVI system uses a self-expanding valve. Both approaches deliver a replacement valve through a catheter rather than open-heart surgery. If approved, Encantor would complement Navitor, giving physicians more options to address individual patient anatomy and clinical needs.

      For U.S. important safety information on Navitor, visit https://abbo.tt/NavitorISI.

      About Abbott:
      Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

      Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. 

      SOURCE Abbott

      Modal title

      Also from this source

      Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke

      Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke

      Abbott (NYSE: ABT), the global healthcare leader, announced today one-year results for its investigational Amulet 360™ Left Atrial Appendage (LAA)...

      Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

      Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

      Abbott (NYSE: ABT), the global healthcare leader, announced strong 30-day results from the TECTONIC Coronary Artery Disease (CAD) Intravascular...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Household, Consumer & Cosmetics

      Household, Consumer & Cosmetics

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.